{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.06","value":"3.56"},{"groupId":"OG001","spread":"1.43","value":"3.13"},{"groupId":"OG002","spread":"1.10","value":"3.32"},{"groupId":"OG003","spread":"1.68","value":"2.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"title":"Single-dose"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"0.697","value":"2.43"},{"groupId":"OG003","spread":"1.55","value":"2.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Multiple-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1","dispersionType":"Standard Deviation","groups":[{"description":"valganciclovir: 450 mg QD or BID VRx-3996: 5 mg BID, 10 mg QD or BID","id":"OG000","title":"Phase 1b Dose Escalation - 450 mg"},{"description":"valganciclovir: 900mg QD or BID VRx-3996: 10 mg QD or BID, 20 mg QD on Days 1 to 4/week","id":"OG001","title":"Phase 1b Dose Escalation - 900 mg"},{"description":"valganciclovir: 900 mg QD VRx-3996: 20 mg QD on Days 1 to 4/week","id":"OG002","title":"Phase 2 RP2D - Capsule (VRx-3996)"},{"description":"valganciclovir: 900 mg QD VRx-3996: 20 mg QD on Days 1 to 4/week","id":"OG003","title":"Phase 2 RP2D - Tablet (VRx-3996)"}],"paramType":"MEAN","populationDescription":"The PK Analysis Set was used for all PK analyses and included all patients in the intent-to-treat population (defined as all enrolled patients) who had at least one postdose measurable PK concentration. The PK Analysis Set will be used for individual plasma concentration listings and summaries of plasma concentrations.","reportingStatus":"POSTED","timeFrame":"Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1","title":"Half-life of Valganciclovir","type":"SECONDARY","unitOfMeasure":"hours"}